Autosomal dominant polycystic kidney disease - PubMed

4 hours ago

ADPKD is the most common genetic cause of chronic kidney disease, leading to significant global morbidity and mortality.
Advances in molecular genetics and imaging have improved diagnostic and prognostic tools for ADPKD.
Tolvaptan is supported as a disease-modifying treatment, especially for high-risk groups.
Management includes screening for complications like cyst infections, intracranial aneurysms, and polycystic liver disease.
The review highlights current approaches to diagnosis, risk assessment, treatment, and clinical management in ADPKD.
New insights into the genetic basis, pathobiology, and potential therapeutic targets are discussed.
A patient-centered care pathway emphasizes shared decision-making with a multidisciplinary team.

Hasty Briefsbeta